Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endovascular Ablation of the Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction - First In-human Feasibility Study

NCT04287946 is registered in ClinicalTrials.gov with Axon Therapies, Inc. as lead sponsor.

NCT NCT04287946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04287946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endovascular Ablation of the Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction - First In-human Feasibility Study
Lead sponsor
Axon Therapies, Inc.
Phase
Not applicable
Overall status
Unknown status
Start date
February 1, 2020
Completion date
November 30, 2024
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction